Compare RLMD & RWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLMD | RWT |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | United States |
| Employees | N/A | 351 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.9M | 652.4M |
| IPO Year | 2012 | N/A |
| Metric | RLMD | RWT |
|---|---|---|
| Price | $5.21 | $4.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $12.40 | $6.82 |
| AVG Volume (30 Days) | 1.8M | ★ 3.5M |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 12.83% |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | $26.59 |
| Revenue Next Year | N/A | $22.21 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.55 | $4.19 |
| 52 Week High | $8.00 | $6.97 |
| Indicator | RLMD | RWT |
|---|---|---|
| Relative Strength Index (RSI) | 35.70 | 47.12 |
| Support Level | $4.06 | $4.19 |
| Resistance Level | $7.28 | $4.97 |
| Average True Range (ATR) | 0.39 | 0.16 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 21.49 | 43.36 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Redwood Trust Inc is a specialty finance company focused on several distinct areas of housing credit. The company delivers customized housing credit investments to a diverse mix of investors through securitization platforms, whole-loan distribution activities, and its publicly traded securities. The company has four reportable segments: Sequoia Mortgage Banking, CoreVest Mortgage Banking, Redwood Investments, and Legacy Investments. Maximum revenue is generated from the Sequoia Mortgage Banking segment, comprising a mortgage loan conduit that acquires residential consumer loans from third-party originators for subsequent sale to whole loan buyers, securitization through its SEMT private-label securitization program, or transfer into its Redwood Investments portfolio.